La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
23 hedge funds and large institutions have $30.3M invested in La Jolla Pharmaceutical Company in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
93% more capital invested
Capital invested by funds: $15.7M → $30.3M (+$14.6M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
4% less funds holding
Funds holding: 24 → 23 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$8.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$7.95M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.45M |
| 4 |
BC
Broadfin Capital
New York
|
+$800K |
| 5 |
SIM
SSI Investment Management
Los Angeles,
California
|
+$313K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.61M |
| 2 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$456K |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$416K |
| 4 |
SIM
Spark Investment Management
New York
|
-$300K |
| 5 |
Renaissance Technologies
New York
|
-$296K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| – | -$300K | -27,800 | Closed |
|
|
27
Renaissance Technologies
New York
| – | -$296K | -27,400 | Closed |
|
28
Jane Street
New York
| – | -$220K | -20,381 | Closed |
|
|
CS
29
Credit Suisse
Zurich,
Switzerland
| – | -$199K | -18,437 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$6K | -542 | Closed |
|
LJPC Hedge Fund Activity: Q2 2014 in Review
23 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2014, worth a combined $30.3M — up 93% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LJPC and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.
The largest buyer was Franklin Resources, opening a new position worth an estimated $8.4M. The largest seller was EAM Investors, exiting entirely with an estimated $1.61M sold.
- 23 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2014, down from 24 in Q1 2014.
- Funds reported $30.3M of La Jolla Pharmaceutical Company stock for Q2 2014, up 93% quarter-over-quarter.
- 6 funds opened new La Jolla Pharmaceutical Company positions in Q2 2014 and 7 closed out, a net change of -1 holder.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2014 was Franklin Resources, an estimated $8.4M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2014 was EAM Investors, an estimated $1.61M sold.
Based on aggregated 13F filings for Q2 2014.